Inactive Instrument

Highlights VIVUS, Inc.

Stocks

VVUSQ

US9285513084

Pharmaceuticals

Highlights

30/04	VIVUS BV Announces Qsiva Price Reduction Across Nordics And Poland	CI
18/03	Vivus BV Confirms QSIVA Price Reduction Is Now Effective Across Nordics And Poland	CI
10/03	Vivus Bv, A Subsidiary of Vivus Llc Announces Qsiva Price Reduction Across Nordics and Poland	CI
26/01	VIVUS LLC Announces the Results of a Randomized Trial Evaluating the Effect of QSYMIA	CI
07/01	VIVUS Introduces Lower Pricing on QSYMIA at Costco Locations Across Hawaii	CI
04/25/04	VIVUS Showcases Leadership in Obesity Management at the 2025 International Congress on Obesity and MEtabolic Syndrome	CI
27/25/27	VIVUS Announces Qsymia Now Available at Costco Pharmacies Nationwide	CI
14/25/14	VIVUS Announces Enrollment of First Patient in Phase 2 Clinical Trial Assessing Ethanol-Free Carmustine as a Component of High-Dose Chemotherapy Prior to Transplant in Patients with Hodgkin or Non-Hodgkin Lymphoma	CI
10/25/10	VIVUS Launches QSYMIA in the United Arab Emirates	CI
23/24/23	VIVUS Announces Label Update for QSYMIA	CI
30/24/30	Vivus, Inc. Announces the Publication of New Clinical Trial Data Demonstrating That Pancreaze Helped to Stabilize Weight in Patients Undergoing Chemotherapy for the Treatment of Pancreatic Ductal Adenocarcinoma	CI
22/24/22	VIVUS LLC Announces It Will Provide Telehealth to Patients Through an Enhanced 'Engage' Program in Collaboration with UpScriptHealth	CI
28/23/28	VIVUS LLC Announces Positive Topline Data from a Post-Marketing Study to Evaluate the Effect of QSYMIA	CI
20/22/20	FDA Approves VIVUS LLC's QSYMIA® for the Treatment of Obesity in Adolescents Ages 12-17	CI
07/20/07	Vivus, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020	CI
06/20/06	VitalTech Partners with VIVUS, Inc. to Accelerate Launch of Telehealth and Remote Patient Monitoring Modules	CI
31/20/31	VIVUS, Inc. Accelerates the Launch of Telemedicine and Remote Monitoring Modules to Facilitate Effective Patient Care During “Social Distancing”	CI
04/20/04	Vivus, Inc. Reports Earnings Results for the Full Year Ended December 31, 2019	CI
02/20/02	VIVUS, Inc. Announces Completion of Patient Enrollment in a Phase 4 Clinical Study Designed to Evaluate the Safety and Efficacy of Qsymia	CI
19/20/19	VIVUS, Inc. and Alvogen Announce Commercial Launch of Qsymia®	CI
05/20/05	VIVUS, Inc. Receives U.S. Food and Drug Administration Approval for Improved Formulation of PANCREAZE with a 36-Month Shelf Life	CI
07/20/07	VIVUS, Inc. Announces New Study from the Toolbox Trial	CI
18/19/18	VIVUS, Inc. Announces New Data Supporting the Safety and Efficacy of Qsymia® in Adolescents with Obesity	CI
20/19/20	VIVUS, Inc. Announces Results of a Clinical Study Demonstrating Patients with Binge-Eating Disorder or Bulimia Nervosa	CI
06/19/06	Vivus, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019	CI